Mersana Therapeutics Reports Q1 2025 Earnings, Faces Revenue Shortfall Amid Stock Volatility
Mersana Therapeutics reported a disappointing Q1 2025 with a revenue shortfall and GAAP loss, but remains committed to advancing its oncology treatments.
2 minutes to read